A breast cancer diagnosis brings immediate questions — and some of the most important ones are questions most patients don't yet know to ask: "What does the receptor test show?" and "Does my cancer need surgery first — or chemotherapy first?" The answers to these questions, more than anything else, determine the treatment plan. Two women diagnosed with breast cancer in the same week can have completely different treatment pathways, and both can be exactly right for their specific cancer.
After a breast cancer diagnosis is confirmed, the biopsy sample undergoes a specific set of tests that determine the entire treatment plan. These are receptor tests — checking whether the cancer is being driven by specific proteins. No treatment plan can be finalised without them:
These four results classify every breast cancer into one of three main treatment groups:
The cancer is driven by oestrogen and/or progesterone, but does not overproduce HER2. Hormone therapy is the cornerstone, given as daily tablets for 5 to 10 years. Chemotherapy is used selectively — a gene expression test on the tumour can predict which patients truly benefit from chemotherapy and which can safely skip it. Long-term prognosis is generally favourable, particularly for early-stage disease.
The cancer overproduces the HER2 protein, making it grow rapidly. Twenty years ago, HER2-positive breast cancer was one of the most feared subtypes. Today, targeted antibody medicines that specifically block HER2 have transformed its outlook — HER2-positive breast cancer now has among the highest complete response rates of all breast cancer types with modern treatment.
The cancer is negative for ER, PR, and HER2 — it is not driven by oestrogen, progesterone, or HER2. Hormone therapy and HER2-targeted medicines do not work. TNBC is treated with chemotherapy, and increasingly with immunotherapy. Despite its reputation as the most aggressive subtype, TNBC responds very well to chemotherapy — and when a complete response is achieved before surgery, long-term outcomes are excellent.
For most women with early-stage breast cancer, a lumpectomy (removing the tumour while keeping the breast) combined with radiation therapy achieves the same long-term survival as mastectomy. The choice depends on tumour size, location, breast size, patient preference and genetic factors — not on which operation gives a better chance of survival.
Breast cancer is most easily treated when found early — often before symptoms appear, through routine screening. Symptoms to watch for include:
Most breast lumps — particularly in younger women — are not cancer. But any change that persists for more than 2 to 4 weeks, or that is accompanied by other symptoms, should be evaluated with imaging and specialist assessment.
Most women diagnosed with breast cancer have no identifiable high-risk factor other than age. Risk factors inform screening decisions and genetic testing referral — they do not determine prognosis once cancer is diagnosed.
Mammography is the standard breast cancer screening tool for women over 40. Ultrasound is used alongside mammography for denser breasts (common in Indian women), to characterise lumps, and to guide needle biopsy. Breast MRI is used for high-risk women (BRCA carriers) and for assessing disease extent before surgery.
A thick needle is guided to the suspicious area — using ultrasound or mammography — and multiple tissue cores are taken for laboratory analysis. The pathologist confirms cancer, identifies the tumour type, and performs the receptor tests (ER, PR, HER2, Ki-67) that determine the treatment plan. Done as a day procedure under local anaesthetic.
For early-stage breast cancer, no additional imaging is needed before treatment planning. For larger tumours, clinical lymph node involvement, or HER2-positive and triple-negative cancers, a CT scan of the chest, abdomen, and pelvis and a bone scan assess for distant spread before treatment begins.
For selected high-risk cases and for assessing treatment response after neoadjuvant chemotherapy, PET-CT is arranged through CION's specialist imaging referral network, starting from ₹9,999 to ₹16,000.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your receptor test, your stage, your preferences — they all shape what's right for you. Talk to a specialist before any decision is finalised.
Breast cancer is staged using the AJCC TNM system. The stage, combined with the receptor subtype, determines the treatment approach and prognosis. Tap any card to see how tumour size, lymph-node spread, primary treatment and 5-year outlook line up for each stage.
One of the most important and most misunderstood facts in breast cancer treatment: for the majority of women with early-stage breast cancer, removing the entire breast does not improve survival over removing just the tumour. Decades of clinical evidence have confirmed that lumpectomy (breast-conserving surgery) followed by radiation therapy achieves equivalent long-term survival to mastectomy — while preserving the breast. This does not mean lumpectomy is always appropriate. The decision depends on several factors:
Removes only the tumour and a small margin of surrounding tissue. After surgery, radiation therapy to the remaining breast tissue is standard.
Removes the entire breast. Used when conservation would compromise the cancer outcome or where patient preference favours full removal.
Regardless of whether lumpectomy or mastectomy is performed, the first draining lymph node — the sentinel node — is removed and examined. If it is cancer-free, no further lymph nodes need to be removed, sparing the patient from the swelling and arm problems that can follow full axillary lymph node clearance. If cancer is found in the sentinel node, further surgery or radiation to the axilla is planned based on the clinical situation.
For breast cancers that are positive for oestrogen receptor (ER+) — approximately 70% of all breast cancers — oestrogen acts as a fuel that drives cancer cell growth. Hormone therapy removes or blocks this fuel and is one of the most effective and important treatments in breast cancer.
For advanced or metastatic ER-positive, HER2-negative breast cancer, targeted daily tablets that slow cancer cell division (CDK4/6 inhibitors) are given alongside hormone therapy. This combination has significantly improved outcomes for advanced ER-positive breast cancer, converting it into a disease that can be controlled for several years.
HER2-positive breast cancer overproduces a protein on the cancer cell surface called HER2 that drives rapid cell division. The development of targeted antibody medicines that specifically block HER2 has been one of the most transformative advances in breast cancer oncology.
The standard treatment for HER2-positive breast cancer combines two different HER2-blocking antibody medicines — trastuzumab and pertuzumab — given alongside chemotherapy as intravenous infusions every 3 weeks. These antibodies attach to the HER2 protein, block the growth signal it sends, and also help the immune system recognise and destroy HER2-positive cancer cells. The combination achieves complete response in the breast and lymph nodes before surgery (a pCR) in more than 60% of patients with early HER2-positive breast cancer — making it one of the most treatment-responsive cancers in oncology.
After surgery, patients who do not achieve a complete response continue with further HER2-targeted treatment for up to a year. Patients who do achieve a complete response receive trastuzumab alone to complete a full year of anti-HER2 therapy.
HER2-positive breast cancer — once considered the most feared subtype because of its rapid growth — is now one of the most treatable forms of breast cancer. With dual HER2-targeted antibody treatment alongside chemotherapy before surgery, more than 60% of patients achieve a complete response: no cancer cells found in the breast or lymph nodes at the time of surgery. If you have been diagnosed with HER2-positive breast cancer, ask your oncologist about dual HER2-blockade before surgery.
For HER2-positive and triple-negative breast cancers, chemotherapy is now routinely given before surgery rather than after. This sequence — called neoadjuvant chemotherapy — offers advantages that post-surgery chemotherapy cannot:
Triple-negative breast cancer (TNBC) is negative for ER, PR, and HER2 — which means it cannot be treated with hormone therapy or HER2-targeted medicines. It grows faster than hormone receptor-positive breast cancer and requires chemotherapy as the main systemic treatment. Despite its aggressive reputation, TNBC tends to respond very well to chemotherapy — and when it achieves a complete response to neoadjuvant chemotherapy, long-term outcomes are excellent. For early-stage TNBC, the treatment sequence is:
Typically 16 to 24 weeks of chemotherapy. For patients whose tumours express a specific protein called PD-L1, an immunotherapy medicine is added alongside chemotherapy before and after surgery; this combination significantly increases the rate of complete response and improves event-free survival.
After neoadjuvant chemotherapy; the surgical specimen shows whether pathological complete response (pCR) has been achieved.
Further immunotherapy to complete a course of approximately one year total in eligible patients.
Additional chemotherapy after surgery to reduce the risk of recurrence.
After surgery for most patients.
For patients with TNBC who also carry a BRCA gene mutation, targeted medicines called PARP inhibitors — which block a protein that cancer cells with BRCA mutations rely on for DNA repair — are given in the adjuvant setting after primary treatment to further reduce recurrence risk.
BRCA1 and BRCA2 are genes that normally help repair damaged DNA. When either gene carries an inherited fault, the DNA repair system fails — dramatically increasing the lifetime risk of breast cancer (up to 70% for BRCA1) and ovarian cancer (up to 40% for BRCA1). BRCA testing is done on a blood or saliva sample and is recommended for breast cancer patients in the following situations:
BRCA-mutated patients with certain breast cancer subtypes are eligible for PARP inhibitor targeted therapy after primary treatment; this significantly reduces recurrence risk.
BRCA-positive women have a high risk of cancer developing in the other breast; the option of bilateral mastectomy is discussed at the time of surgery planning.
A positive BRCA result has implications for first-degree relatives (daughters, sisters, mother), who can be offered testing and, if positive, early surveillance and risk-reduction options.
CION arranges BRCA testing for all eligible patients. Results are discussed with the patient and family in a structured genetic counselling conversation.
When mastectomy is the recommended or preferred surgery, patients are often so focused on the cancer treatment that reconstruction is not raised — or it is mentioned but dismissed as a cosmetic concern. At CION, we raise reconstruction as a routine part of mastectomy planning for every eligible patient. Immediate breast reconstruction — performed at the same operation as the mastectomy — does not delay cancer treatment, does not worsen oncological outcomes, and dramatically improves quality of life and body image compared to mastectomy alone.
A temporary tissue expander placed at the time of mastectomy is later replaced with a permanent implant. The most commonly used approach for immediate reconstruction.
Using the patient's own tissue from the back, abdomen, or thigh to reconstruct the breast. More complex but avoids implants and produces a natural result.
Not every patient is eligible for immediate reconstruction. Factors including the need for post-mastectomy radiation, medical fitness, and patient preference all influence the timing and type of reconstruction. Delayed reconstruction — performed months or years after mastectomy — is also an option for women who did not have immediate reconstruction. CION's surgical oncology team discusses reconstruction options with every patient undergoing mastectomy and coordinates with plastic surgery partners for reconstruction procedures.
Breast cancer management requires medical oncology, surgical oncology, radiation oncology, radiology, and pathology working together from diagnosis. At CION, every case is reviewed before treatment begins:
Treatment costs vary based on stage, subtype, and the combination of surgery, chemotherapy, targeted therapy, and radiation required. The figures below are indicative and a personalised estimate is provided following your initial oncology consultation at CION.
| Treatment / Investigation | Approx. Cost (INR) | Notes |
|---|---|---|
| Core Needle Biopsy (with receptor testing) | ₹8,000 – ₹20,000 | ER, PR, HER2, Ki-67 included in pathology |
| BRCA Gene Testing | ₹15,000 – ₹40,000 | Blood or saliva sample; result in 2–4 weeks |
| PET-CT Scan | ₹9,999 – ₹16,000 | Through CION's specialist imaging referral network |
| Lumpectomy (Breast-Conserving Surgery) | ₹80,000 – ₹2,50,000 | Includes sentinel node biopsy; 1–2 day stay |
| Mastectomy (Simple or Skin-Sparing) | ₹1,50,000 – ₹3,50,000 | Includes sentinel node biopsy; 2–3 day stay |
| Breast Reconstruction (Implant-Based) | ₹1,50,000 – ₹4,00,000 | Immediate at time of mastectomy; implant cost included |
| Radiation Therapy — Whole Breast (after lumpectomy) | ₹1,20,000 – ₹2,50,000 | 5–6 week course; standard after lumpectomy |
| Chemotherapy (per cycle, standard regimen) | ₹30,000 – ₹80,000 | For adjuvant or neoadjuvant use; 4–8 cycles |
| HER2-Targeted Antibody Therapy — Trastuzumab (per cycle) | ₹60,000 – ₹1,50,000 | Every 3 weeks for 1 year; biosimilars at lower cost |
| Trastuzumab + Pertuzumab Dual HER2-Blockade (per cycle) | ₹1,20,000 – ₹2,50,000 | Standard for neoadjuvant HER2+ treatment |
| Hormone Therapy — Tamoxifen / Aromatase Inhibitors (monthly) | ₹500 – ₹5,000 | 5–10 years; generics widely available |
| CDK4/6 Inhibitor Tablets for Advanced ER+ Disease (monthly) | ₹80,000 – ₹2,00,000 | Generics available at lower cost; ongoing |
| PARP Inhibitor for BRCA-Mutated Breast Cancer (monthly) | ₹80,000 – ₹1,80,000 | For BRCA1/2 mutation carriers |
Costs are indicative. Targeted therapy and hormone therapy costs are significantly reduced by generic and biosimilar medicines now widely available in India. EMI facility — flexible instalment-based payment options available for all patients. Private Health Insurance — CION works with all major TPAs for cashless hospitalisation.
If mastectomy was recommended without discussing lumpectomy — or HER2 dual-blockade wasn't offered — a second opinion is worth your time.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.The most common symptom is a new lump or thickening in the breast or armpit that feels different from the surrounding tissue. Other symptoms include: a change in the size or shape of one breast; dimpling, puckering, or an orange-peel texture on the breast skin; a nipple that has turned inward, or nipple discharge that is not breast milk; scaling or crusting of the nipple skin; persistent unexplained breast or nipple pain; and redness or warmth of the breast skin. Most breast lumps are benign — but any new lump or change that persists for more than 2 to 4 weeks should be evaluated with ultrasound and specialist assessment.
For early-stage breast cancer (Stage I and II), cure rates are very high: 95 to 99% for Stage I and 75 to 90% for Stage II. Stage III breast cancer has 50 to 75% 5-year survival with comprehensive treatment. Stage IV (metastatic) breast cancer is generally not curable, but it is increasingly manageable for prolonged periods — particularly ER-positive breast cancer (controlled for years with hormone therapy and CDK4/6 inhibitor tablets) and HER2-positive breast cancer (where targeted treatment has transformed long-term outcomes). HER2-positive breast cancer achieving a complete response to neoadjuvant chemotherapy has excellent 10-year survival rates approaching those of hormone receptor-positive breast cancer.
A lumpectomy (breast-conserving surgery) removes only the tumour and a small margin of surrounding tissue, preserving the rest of the breast. It is followed by radiation therapy to reduce the risk of local recurrence. A mastectomy removes the entire breast. Clinical evidence from decades of trials shows that for eligible early-stage patients, lumpectomy plus radiation achieves the same long-term survival as mastectomy. The choice between them depends on tumour size, location, patient preference, genetic factors (BRCA status), and willingness to have radiation. Many women who initially assume they need mastectomy discover after specialist consultation that lumpectomy is a safe and suitable option.
HER2-positive breast cancer overproduces a protein on the cell surface called HER2 (Human Epidermal Growth Factor Receptor 2) that drives rapid cell division. It accounts for approximately 20% of all breast cancers. Twenty years ago, it was one of the most aggressive subtypes. Today, targeted antibody medicines that specifically attach to and block the HER2 protein — trastuzumab and pertuzumab — given alongside chemotherapy have transformed its outlook. Complete response rates in the breast and lymph nodes before surgery now exceed 60% with dual HER2-blockade, making HER2-positive breast cancer one of the most treatment-responsive subtypes.
Triple-negative breast cancer (TNBC) is negative for all three receptor markers: oestrogen receptor (ER-), progesterone receptor (PR-), and HER2. It cannot be treated with hormone therapy or HER2-targeted medicines. It accounts for 10 to 15% of breast cancers and grows faster than hormone receptor-positive breast cancer. However, TNBC responds very well to chemotherapy — and when a complete response to neoadjuvant chemotherapy is achieved before surgery (no cancer cells remaining), long-term outcomes are excellent. For eligible patients, adding an immunotherapy medicine alongside chemotherapy improves the complete response rate and overall outcomes. BRCA mutation testing is recommended for all TNBC patients.
Neoadjuvant chemotherapy means giving chemotherapy before surgery rather than after. For HER2-positive and triple-negative breast cancers, this sequence offers significant advantages: it shows whether the chemotherapy is working (by monitoring tumour shrinkage on examination and imaging); it can shrink a large tumour to allow breast-conserving surgery where mastectomy would otherwise be needed; and it creates a "test result" — if all cancer is gone from the breast and lymph nodes before surgery (a pathological complete response), this predicts excellent long-term outcomes. If response is incomplete, additional treatment after surgery reduces recurrence risk.
Not necessarily. For most women with early-stage breast cancer, a lumpectomy — removing the tumour while keeping the breast — combined with radiation therapy achieves the same long-term survival as mastectomy. Mastectomy is recommended when: the tumour is large relative to breast size; there are multiple separate tumours in the breast; inflammatory breast cancer is present; the patient carries a BRCA1 or BRCA2 mutation; or the patient prefers mastectomy. The decision is made in a shared discussion between the patient and surgical oncologist, taking into account both clinical factors and the patient's own priorities and preferences.
BRCA1 and BRCA2 are genes that normally repair damaged DNA. An inherited fault in either gene dramatically increases lifetime risk of breast cancer (up to 70% for BRCA1) and ovarian cancer. BRCA testing uses a blood or saliva sample. It is recommended for: breast cancer diagnosed under 45; triple-negative breast cancer under 60; a family history of breast cancer in a first-degree relative, particularly under 50; a family history of ovarian cancer; bilateral breast cancer; or both breast and ovarian cancer in the family. BRCA-positive patients may be eligible for PARP inhibitor treatment after primary therapy, and the result has important implications for first-degree relatives who can be offered testing.
Lumpectomy: ₹80,000–₹2,50,000. Mastectomy: ₹1,50,000–₹3,50,000. Implant-based breast reconstruction: ₹1,50,000–₹4,00,000. Radiation therapy (whole breast): ₹1,20,000–₹2,50,000. Chemotherapy (per cycle): ₹30,000–₹80,000. HER2-targeted therapy (trastuzumab per cycle, biosimilar): ₹60,000–₹1,50,000. Hormone therapy (monthly): ₹500–₹5,000 for generics. CDK4/6 inhibitors (monthly): ₹80,000–₹2,00,000. PET-CT: ₹9,999–₹16,000. BRCA testing: ₹15,000–₹40,000. A personalised estimate is provided after your initial CION consultation. EMI options are available.
Absolutely — and for breast cancer, a second opinion is valuable in three situations: if mastectomy has been recommended without a discussion of whether lumpectomy is feasible for your tumour size and location; if you have HER2-positive breast cancer and have not been offered dual HER2-blockade (trastuzumab + pertuzumab) alongside chemotherapy before surgery — this combination is the standard of care; and if you have triple-negative breast cancer or a diagnosis under 45 and BRCA testing has not been discussed — this testing has direct implications for treatment choice and your family. CION offers a dedicated Second Opinion service.
